| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 238,554 | 297,872 | 211,526 | 93,775 |
| Restricted cash | 321 | 319 | 318 | 323 |
| Short-term investments | 0 | 0 | 149,789 | 393,122 |
| Prepaid expenses and other current assets | 7,591 | 11,049 | 9,118 | 2,410 |
| Research and development tax credit receivable | - | - | - | 660 |
| Total current assets | 246,466 | 309,240 | 370,751 | 490,290 |
| Property and equipment, net | 810 | 690 | 652 | 265 |
| Operating lease right-of-use assets | 5,420 | 5,552 | 6,351 | 7,976 |
| Goodwill | 1,999 | 2,039 | 1,923 | 1,991 |
| Research and development tax credit receivable | - | - | - | 467 |
| Other assets | 7,034 | 6,516 | 4,145 | 1,863 |
| Total assets | 261,729 | 324,037 | 383,822 | 502,852 |
| Accounts payable | 22,245 | 22,982 | 4,994 | 3,252 |
| Accrued liabilities | 27,042 | 26,148 | 21,185 | 18,477 |
| Accrued compensation | 10,965 | 6,592 | 4,396 | 7,961 |
| Operating lease liabilities, current portion | 2,720 | 3,118 | 3,543 | 3,792 |
| Other current liabilities | 1,956 | 1,485 | 759 | 1,027 |
| Promissory note payable to a related party | - | - | - | 24,500 |
| Total current liabilities | 64,928 | 60,325 | 34,877 | 59,009 |
| Operating lease liabilities, net of current portion | 2,708 | 2,435 | 2,907 | 4,207 |
| Other non-current liabilities | 1,830 | 1,838 | 1,708 | 1,716 |
| Promissory note payable to a related party | - | - | - | 0 |
| Total liabilities | 69,466 | 64,598 | 39,492 | 64,932 |
| Common stock, 0.01 par value 1,000,000,000 shares authorized 744,442,533 and 737,626,004 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 7,444 | 7,428 | 7,416 | 7,371 |
| Additional paid-in capital | 2,262,515 | 2,097,957 | 1,616,963 | 1,586,227 |
| Accumulated other comprehensive loss | -2,709 | -2,752 | -2,563 | -2,308 |
| Accumulated deficit | -2,074,987 | -1,843,194 | -1,277,486 | -1,153,370 |
| Total stockholders' equity | 192,263 | 259,439 | 344,330 | 437,920 |
| Total liabilities and stockholders' equity | 261,729 | 324,037 | 383,822 | 502,852 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)